MVA-member, BioInnovation Institute, awards EUR 14M to eight innovative and promising start-ups and research projects

Sep 23, 2020

The start-ups and research projects work within the three life science industries: therapeutics, health tech and bioindustrials. The start-ups and projects are developing a diverse range of products and solutions ranging from using an innovative approach to using CRISPR Cas-12 variants to be safely used in gene-editing, a new amyotrophic lateral sclerosis (ALS) treatment, a gut approach to treating osteoporosis, a range of biological products against aquatic pests and diseases, and the development of new therapies for diabetic retinopa­thy to prevent vision loss and blindness in patients.

Jens Nielsen, professor, and CEO at BioInnovation Institute says: “BII helps early-stage start-ups become investment ready by bridging the gap between academia and business. I am happy to welcome the new high-potential companies and research projects in BII’s community to provide them with the best opportunities to develop their innovation. I am looking forward to following the companies’ accelerated path towards the market with the knowledge, network, funding, and infrastructure required for start-up success.”

Read full press release from BII here and learn which companies and projects are now part of the BII- and Medicon Valley Alliance family.

Most recent news